Caining J.

Caining J. is a Principal Scientist at Recipharm, focusing on the development of mRNA high-throughput screening platforms since November 2023. Previously, Caining served as Associate Director and Head of RNA Biology at Hopewell Therapeutics, Inc., where the mRNA Biology Department was established and managed from January 2022 to September 2023. Caining also contributed to analytical development in the DMPK Department at Stoke Therapeutics, supporting clinical trials for ASO drugs. Earlier roles included Co-Associate Director at the Harvard GSAS Business Club, organizing entrepreneurship events, and serving as a Senior Scientist at Genus Oncology LLC / DFCI, conducting R&D on ADC drug candidates. Education includes a Ph.D. in Molecular Immunology from Peking University and a Research Fellowship at HMS - MGH/DFCI, along with ongoing training as a Retirement Income Certified Professional at The American College of Financial Services.